
Immunofluorescence (IF) is an immunochemical staining technique that utilizes fluorochrome-labeled antibodies for the visualization and localization of targets, by labelling with a fluorescent dye such as fluorescein isothiocyanate (FITC). It can identify a wide range of components on tissue sections, cultured cells, or individual cells, and is thus highly valuable for their broad capability with the use of combinations of specific antibodies tagged with fluorophores.
There are several steps for IF, with the first being fixation to immobilize target antigens while maintaining cellular architecture. Next, sample preparation and blocking needs to be carried out to prevent non-specific binding of antibodies. Then, incubation of primary and secondary antibodies take place before the final preservation and imaging.
There are two different IF methods available: Direct (Primary) and Indirect (Secondary). Direct detection requires using a single fluorochrome-conjugated primary antibody. Meanwhile, indirect detection uses two antibodies, with the first being an unlabeled primary antibody, followed by a fluorochrome-conjugated secondary antibody.
Although both monoclonal and polyclonal antibodies can be used for IF, they have their own pros and cons. Indirect IF more commonly used as the secondary antibodies are typically polyclonal, allowing for the recognition of multiple epitopes of the targets. However, monoclonal antibodies which are specifically designed for IF may be more preferable if your research involves recognizing very specific targets.1
At Biointron, we are dedicated to accelerating your antibody discovery, optimization, and production needs. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.
Im, K., Mareninov, S., Diaz, M. F. P., & Yong, W. H. (2019). An introduction to Performing Immunofluorescence Staining. Methods in Molecular Biology (Clifton, N.J.), 1897, 299. https://doi.org/10.1007/978-1-4939-8935-5_26
March 2026 saw a surge in antibody dealmaking, focusing on T-cell engagers and a……
Clinical drug development remains associated with a high failure rate, primarily……
Read on for the key trends of the NextGen Biomed 2026 conference held in London ……
Biointron’s Networking Lunch (At the Table: Antibody Discovery) was held at Cata……
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
Biointron uses cookies and similar technologies to ensure proper website functionality, understand how visitors use our website, and improve our content and services. Necessary cookies are enabled by default.
By clicking “Accept All”, you agree to the use of all cookies, including analytics and optional cookies that help us understand website usage and improve user experience. By clicking “Reject Non-Essential”, only necessary cookies will be used.
You may manage or change your cookie preferences at any time by clicking “Cookie Settings” at the bottom of the website.
For more information about how we use cookies and process personal data, please review our Privacy Policy.



